REG - Allergy Therapeutics - Result of General Meeting

Allergy TherapeuticsAnnouncement

31/07/2023 14:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230731:nRSe7738Ha&default-theme=true

RNS Number : 7738H  Allergy Therapeutics PLC  31 July 2023

Allergy Therapeutics plc

("Allergy Therapeutics", the "Company" or the "Group")

 

Result of General Meeting

 

31 July 2023: Allergy Therapeutics plc (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy vaccines, announces
that at the General Meeting today, held for the purposes of approving the
Company's annual report and accounts for the year ended 30 June 2022 (the
"2022 Accounts"), all resolutions were duly passed.

 

All resolutions were voted on by way of a poll. The results of the poll were
as follows:

 

 Resolution                                                        Votes For    % of votes for    Votes Against  % of votes against  Votes Withheld  Total votes cast
 1. To receive the Directors' report, the consolidated financial   332,831,805  99.75%            822,693        0.25%               97,047          333,751,545

 statements and the auditors' report of the Company for the year

 ended 30 June 2022 (the "2022 Accounts")
 2. To approve the Directors' remuneration report, as set out on   330,801,478  99.27%            2,443,679      0.73%               506,388         333,751,545

 pages 64 to 72 of the 2022 Accounts

 

 

- ENDS -

 

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

+44 (0)1903 845 820

 

Panmure Gordon (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

+44 (0)20 7886 2500

 

Consilium Strategic Communications

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMXFLFXXDLXBBF